Key Points Annexon added a Month 24 dual-primary endpoint to the ongoing ARCHER II Phase 3 trial of vonapramide in geographic atrophy. The original Month…
August 11, 2026
AC Immune Speeds Toward a Potential Parkinson’s Breakthrough with FDA Fast Track Status
Key Points AC Immune received FDA Fast Track designation for ACI-7104, its investigational active immunotherapy for early Parkinson’s disease. The company also received FDA clearance…
Key Points Scholar Rock said the FDA review of apitegromab for spinal muscular atrophy is progressing with the company’s second fill-finish manufacturing facility. The company…
Key Points Silence Therapeutics reported $72.1 million in cash and cash equivalents at the end of Q2 2026. Net loss narrowed to $12.3 million, or…
Ahead of Nuvation Bio’s (NYSE: NUVB) second-quarter results, investors were looking for evidence that the company’s strong first quarter represented the beginning of a sustainable…
August 06, 2026
Vistagen’s Repeat-Dose Study Supports Fasedienol’s Potential in Social Anxiety Disorder
Key Points Vistagen reported topline results from an exploratory Phase 2 repeat‑dose study of fasedienol nasal spray for the acute treatment of social anxiety disorder….
July 30, 2026
Cingulate’s Phase 3 CTx‑1301 ADHD Results Published in Leading Child & Adolescent Psychiatry Journal
Key Points Phase 3 pediatric trial results for CTx‑1301 (dexmethylphenidate) in ADHD have been published in a respected child and adolescent psychopharmacology journal, adding peer‑reviewed…
Key Points CMND‑100 has been well tolerated across several dosing groups, including higher doses, with no serious adverse events reported. An independent safety board has…
Allogene Therapeutics has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for an allogeneic CAR‑T candidate in large B‑cell lymphoma. Early data show a disease…
July 28, 2026
Atea’s Hepatitis C Breakthrough: New Short‑Course Pill Regimen Clears Phase 3 C‑BEYOND Trial
Phase 3 C‑BEYOND in hepatitis C met both primary and secondary goals. Atea’s pill combo bemnifosbuvir/ruzasvir showed very high cure rates and a solid safety…
July 28, 2026
Perspective Therapeutics Gains European Orphan Status for Targeted GEP‑NET Radiotherapy
Perspective Therapeutics (NYSE: CATX) received orphan medicinal product designation in Europe for its radiopharmaceutical candidate [212Pb]VMT‑α‑NET targeting gastroenteropancreatic neuroendocrine tumors (GEP‑NETs). Orphan status in the…
July 27, 2026
Capricor stock falls as FDA raises fresh questions
Capricor Therapeutics (NASDAQ: CAPR) came under pressure after the FDA released briefing documents ahead of the company’s July 29 advisory committee meeting for deramiocel, its…